Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, announced on August 24th a multi-target strategic collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). Through this partnership ShapeTX will apply its proprietary RNA editing platform RNAfix™ and potentially leverage its AAVid™ technology platform for next-generation tissue-specific adeno-associated viruses (AAVs) for the development of gene therapy for certain targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases. During the course of the partnership, ShapeTX will conduct preclinical research to identify and deliver development candidates discovered by its AI-powered platforms RNAfix™ and, potentially, AAVid™. Roche will be responsible for the development and worldwide commercialization of any potential products resulting from the collaboration.
For further information, see Globenewswire (https://www.globenewswire.com/news-release/2021/08/24/2285515/0/en/Shape-Therapeutics-enters-into-a-strategic-research-collaboration-with-Roche-to-advance-breakthrough-AAV-based-RNA-editing-technology-for-neuroscience-and-rare-disease-indications.html)